Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
复制标题
DOI：
10.1007/s10549-018-05125-4
复制
发表时间：
2019-04-01
影响因子：
3.8
通讯作者：
Slamon, D. J.
中科院分区：
文献类型：
--
作者：
Rugo, H. S.;Finn, R. S.;Slamon, D. J.
目的在中位随访 23 个月的初始 PALOMA-2 (NCT01740427) 分析中，哌柏西利联合来曲唑显着延长雌激素受体阳性 (ER+)/人表皮生长因子受体 2 阴性 (HER2-) 晚期乳腺癌 (ABC) 女性的无进展生存期 (PFS) [风险比 (HR) 0.58；磷
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P